PolarityTE Inc

PolarityTE, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. PolarityTE was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RegenETP, Inc. is a biotechnology company developing and commercializing regenerative tissue products and biomaterials. The firm's products include SkinTE Cryo, SkinTE POC, PTE 11000, OsteoTE and Real Time Assistant. Its SkinTE product is commercially available for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The firm operates through the following segments: regenerative medicine products and contract services. It was founded on May 8, 1998 and is headquartered in Salt Lake City, UT.

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the second calendar quarter of 2020.

PolarityTE Reports Second Quarter 2020 Results

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Jessica Shen, MD, MS to the Company’s Board of Directors.

PolarityTE Announces the Addition of Clinical Development and Regulatory Affairs Executive Jessica Shen, MD, MS to Board of Directors

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar second quarter 2020 financial results by press release on Thursday, August 6, 2020 at approximately 7:00 a.m.

PolarityTE to Report Second Quarter 2020 Financial Results on August 6, 2020

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced positive results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial evaluating treatment of Diabetic Foot Ulcers with SkinTE plus standard of care (SOC) vs SOC alone (NCT03881254).

PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE™ Diabetic Foot Ulcer Trial

SALT LAKE CITY--(BUSINESS WIRE)--PolarityTE, Inc. (Nasdaq: PTE) announced that data from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial (RCT) entitled “SkinTE™ in the Treatment of Diabetic Foot Wounds” will be featured in a poster presentation at the Symposium on Advanced Wound Care (SAWC) Spring Virtual Conference to be held July 24-26, 2020.

PolarityTE Announces Interim Data from Diabetic Foot Ulcer Trial will be Presented at Symposium on Advanced Wound Care to be Held July 24-26, 2020

Avinger

Carriage Services

Mogo

Teekay Tankers

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Rising P/E: An Overlooked Trick to Pick 5 Winning Stocks

Devon Energy

Halliburton

Las Vegas Sands

It is possible that the markets have run too far making today ideal for taking a few short positions. According to our deep learning algorithms, these are the ones to go after.

Top Companies To Short As US Economy Opens Up

PolarityTE's (PTE) CEO David Seaburg on Q1 2020 Results - Earnings Call Transcript

Shares of PolarityTE (NASDAQ:PTE) were flat in pre-market trading after the company reported Q1 results.

PolarityTE: Q1 Earnings Insights

PolarityTE, Inc.'s (PTE) Management on Q4 2019 Results - Earnings Call Transcript

Shares of PolarityTE Inc. plummeted 46% in premarket trading Wednesday, putting them on track to open at a record low, after the regenerative tissue products and biomaterials company said it priced a public offering of common stock, and warrants to buy to common stock, at a deep discount.

PolarityTE's stock loses nearly half its value after public offering of stocks, warrants

Akcea Therapeutics

AMAG Pharmaceuticals

Axsome Therapeutics

Cronos Group

Eidos Therapeutics Inc

Heron Therapeutics

Ligand Pharmaceuticals

Paratek Pharma

Viking Therapeutics

Intrexon

ZIOPHARM Oncology

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

12 Biotech Stocks Primed For A Short Squeeze

PolarityTE: Turning The Ship Around

PolarityTE, Inc. (PTE) Management on Q3 2019 Results - Earnings Call Transcript

It was a busy few months for PolarityTE including a leadership change and short-term focus shift. Both are welcome, but there is a huge tail risk involved.

PolarityTE: Inflection

PolarityTE, Inc. (PTE) Management on Q2 2019 Results - Earnings Call Transcript

SkinTE is a transformational alternative to STSGs (split-thickness skin grafts), the standard-of-care for severe burns and wounds.

PolarityTE: Pick This Regenerative Medicine Stock In 2019

PolarityTE, Inc. (PTE) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

PolarityTE Enters Oversold Territory

Coeur Mining

Freeport-McMoRan

According to GuruFocus Insider Data, the recent CFO buys were: Freeport-McMoRan Inc, PolarityTE Inc. & Coeur Mining Inc.

Recent buys from company CFOs

Polarityte Inc (NASDAQ: PTE) shares were seeing an upward bounce Monday in reaction to a clinical trial readout at the American Diabetes Association's 79th Scientific Sessions conference.

PolarityTE Shares Rally On Positive Readout From Skin Graft Study In Diabetic Foot Ulcers

PolarityTE has developed a regenerative medical technology that is already showing outstanding results in the clinic.

PolarityTE: All Or Nothing

PolarityTE (PTE) needs investors to pay close attention to the stock based on moves in the options market lately.

Implied Volatility Surging for PolarityTE (PTE) Stock Options

PolarityTE, Inc. (PTE) CEO Denver Lough on Q1 2019 Results - Earnings Call Transcript

Shares drop after the company announces that it is raising capital. Here are the must-know details for investors.

Why PolarityTE Is Sinking Today

Shares plunge after the company reports fourth-quarter results. Here's what investors need to know.

News for PolarityTE Inc Stock (PTE)